Meeting
2018 Genitourinary Cancers Symposium
RX‐3117, an oral hypomethylating agent to treat advanced solid tumors: Interim results from an ongoing phase 2a study in advanced urothelial cancer (aUC).
Authors
Meghan Salgia
City of Hope, Duarte, CA
Meghan Salgia , Sumanta K. Pal , Vincent M. Chung , Scott T. Tagawa , Joel Picus , Hani M. Babiker , Sumati Gupta , Julie Poore , Christine Peterson , Ely Benaim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT02030067
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 501)
DOI
10.1200/JCO.2018.36.6_suppl.501
Abstract #
501
Poster Bd #
K8
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC).
First Author: Jacob Adashek
Poster
2019 Genitourinary Cancers Symposium
Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with advanced urothelial cancer: Preliminary results of a phase IIa study.
First Author: Nicholas Salgia
Poster
2018 Gastrointestinal Cancers Symposium
RX3117: Activity of an oral antimetabolite nucleoside in subjects with pancreatic cancer—Preliminary results of stage II of the phase Ia/IIb study.
First Author: Vincent M. Chung
Poster
2015 ASCO Annual Meeting
A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase 2, to treat subjects with advanced solid tumors.
First Author: Drew Warren Rasco